Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Expands By 21.8%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 8,751 shares, a growth of 21.8% from the March 15th total of 7,185 shares. Based on an average daily volume of 27,194 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Price Performance

NYSEAMERICAN MTNB opened at $0.53 on Friday. The business has a 50 day simple moving average of $0.59 and a 200 day simple moving average of $0.88. Matinas Biopharma has a one year low of $0.48 and a one year high of $3.09. The stock has a market capitalization of $3.37 million, a P/E ratio of -0.26 and a beta of 1.39.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its earnings results on Tuesday, March 31st. The company reported ($0.26) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.